Industry Primer — Healthcare
Pharmaceutical distributors serve as the critical link between drug manufacturers and dispensing points (pharmacies, hospitals, clinics). The U.S. market is a $600B+ oligopoly dominated by McKesson, AmerisourceBergen (Cencora), and Cardinal Health, which collectively control ~90% of drug distribution. These companies operate on thin margins (1-2% operating margin) but generate massive cash flows given revenue scale. The sector also includes specialty distributors and healthcare supply companies serving specific channels.
Fundamentals are strong. Specialty drug distribution is the primary growth driver as biologic and specialty pharmacy volume grows 10-15% annually. GLP-1 distribution volumes are surging. Generic drug pricing has stabilized after years of deflation. Opioid litigation settlements have largely been resolved, removing a major overhang. Biosimilar launch volumes are creating new distribution opportunities. All three major distributors are investing in upstream capabilities — manufacturer services, data analytics, and specialty pharmacy.
Over five years, the distribution model will evolve from logistics-centric to data and services-centric. Specialty pharmacy operations, where distributors handle complex drug administration, patient management, and payer navigation, will be the fastest-growing segment with margins 3-5x core distribution. Cell and gene therapy logistics — requiring ultra-cold chain and patient-specific handling — creates high-value specialized distribution needs. Expect continued margin expansion as specialty mix increases.
Long-term, the three major distributors are well-positioned as essential infrastructure. However, direct-to-patient shipping models, Amazon Pharmacy expansion, and manufacturer direct distribution experiments could erode certain segments. The distributors that build the deepest data and analytics capabilities — connecting prescriber, payer, and patient data — will capture the most value. Healthcare supply chain resilience and reshoring of API manufacturing will create new roles for distribution companies.
Drug price inflation, particularly branded drugs, directly drives revenue growth. Specialty drug mix determines margin trajectory. Generic deflation rates impact sell-side margins. Manufacturer fee-for-service and distribution agreements define economics. Regulatory compliance including drug traceability (DSCSA) creates operational requirements. Working capital management and pharmaceutical inventory financing are critical. Opioid litigation and regulatory risk remain relevant.
AI optimizes distribution operations through demand forecasting that reduces inventory carrying costs and stockouts, route optimization for delivery fleets, and automated warehouse operations. Predictive analytics identify counterfeit or diverted products in the supply chain. AI-powered specialty pharmacy platforms improve medication adherence and patient outcomes. NLP automates prior authorization and benefits verification for specialty drugs.
Pharmaceutical distributors can deploy AI-powered demand forecasting and inventory optimization to reduce carrying costs while maintaining high fill rates — essential for just-in-time distribution in healthcare. Automated order processing and warehouse management systems improve pick accuracy and throughput. Track-and-trace serialization technology (required by DSCSA) can be leveraged as a differentiated service offering. Route optimization for delivery fleets reduces logistics costs.
McKesson (MCK) is the largest pharmaceutical distributor and a leading health IT company. AmerisourceBergen/Cencora (ABC) specializes in specialty distribution and global sourcing. Cardinal Health (CAH) combines pharmaceutical and medical product distribution. Henry Schein (HSIC) distributes dental and medical products. Owens & Minor (OMI) provides medical supply distribution and manufacturing.